昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06127 昭衍新药

提前休市 12-24 12:08:24

21.640

-0.540

-2.43%

最高22.380	最低21.520	成交量272.35万
今开22.180	昨收22.180	日振幅3.88%
总市值162.08亿	流通市值25.75亿	总股本7.49亿
成交额5,953万	换手率2.29%	流通股本1.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":21.64,"timestamp":1766549304005,"preClose":22.18,"halted":0,"volume":2723451,"delay":0,"floatShares":118995206,"shares":749000000,"eps":0.11096854465570201,"marketStatus":"提前休市","change":-0.54,"latestTime":"12-24 12:08:24","open":22.18,"high":22.38,"low":21.52,"amount":59532138,"amplitude":0.038774,"askPrice":21.64,"askSize":2700,"bidPrice":21.58,"bidSize":3800,"shortable":3,"etf":0,"ttmEps":0.3542282398226992,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":6,"adr":0,"listingDate":1614268800000,"exchange":"SEHK","adjPreClose":22.18,"dividendRate":0.001512,"openAndCloseTimeList":[[1766539800000,1766548800000]],"volumeRatio":0.856832,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":35.86,"timestamp":1766559600000,"preClose":35.85,"halted":0,"volume":18051000,"delay":0,"premium":"-45.62"}},"requestUrl":"/m/hq/s/06127","defaultTab":"news","newsList":[{"id":"2593444378","title":"智通港股通占比异动统计|12月24日","url":"https://stock-news.laohu8.com/highlight/detail?id=2593444378","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593444378?lang=zh_cn&edition=full","pubTime":"2025-12-24 08:36","pubTimestamp":1766536569,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，根据2025年12月23日披露数据，狮腾控股、均胜电子、东方电气港股通持股占比增加值最大，分别增加2.12%、1.44%、1.17%；佑驾创新、山东墨龙、浙江世宝港股通持股占比减少值最大，分别减少-1.16%、-1.09%、-0.72%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00553","00358","03033","03347","01357","01072","02498","06693","01952","02865","02603","01138","01057","01709","02570","02587","09688","01798","06166","01635","02727","02273","06127","00699","01071","02643","00568","02160","00119","00187","02579","02465","00839","00175","02562","01896","03678","03323","00552","02431","01880","01528","00038","02648","00638","09696","01341","09927"],"gpt_icon":1},{"id":"2593945005","title":"港股异动 | 昭衍新药(06127)涨超5% 上游实验猴供给端紧张 公允价值变动有望贡献利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2593945005","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593945005?lang=zh_cn&edition=full","pubTime":"2025-12-23 10:43","pubTimestamp":1766457795,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昭衍新药涨超5%，截至发稿，涨5.17%，报22.38港元，成交额1.16亿港元。消息面上，国海证券12月22日研报指出，临床前CRO客户需求回暖，上游实验猴供给端紧张。据方正证券测算，以昭衍新药为例，假设按照2024年实验猴均价计入公允价值8.49万/只，2025Q4价格提升至14万/只，假设猴场出栏率为17%，按照已知23200只猴测算，毛估计2025年新增公允价值约2.2亿。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","603127","BK0216","BK1141","06127"],"gpt_icon":0},{"id":"2593143243","title":"每日卖空追踪 | 昭衍新药 12月22日卖空量成交10.93万股，卖空比例为1.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593143243","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593143243?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:30","pubTimestamp":1766392237,"startTime":"0","endTime":"0","summary":"昭衍新药北京时间12月22日，跌2.74%，卖空量成交10.93万股，较上一交易日减少65.72%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163716a4699879&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163716a4699879&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","06127","BK1141"],"gpt_icon":0},{"id":"2593710420","title":"港股异动 | CRO概念股承压走低 康龙化成(03759)跌超4% 昭衍新药(06127)跌超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593710420","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593710420?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:24","pubTimestamp":1766388287,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念股承压走低，截至发稿，康龙化成跌4.32%，报21.24港元；昭衍新药跌3.29%，报21.16港元；凯莱英跌2.31%，报78.15港元；维亚生物跌1.98%，报1.98港元。信达证券指，过去两年《生物安全法案》是压制CXO板块估值的重要原因，和最初版本相比，最终落地的版本没有点名具体企业，整体相对温和。虑到美联储已经进入降息通道，全球生物医药投融资有望边际改善，随着法案落地，CXO板块有望迎来业绩和估值的双重修复。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03759","BK0216","BK1191","06127","300759","01873","BK1576","06821","603127","BK1141"],"gpt_icon":0},{"id":"2593657109","title":"医药外包概念股逆市受压 康龙化成(03759)跌4.14% 机构指美生物安全法案对华CXO企业经营影响有限","url":"https://stock-news.laohu8.com/highlight/detail?id=2593657109","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593657109?lang=zh_cn&edition=full","pubTime":"2025-12-22 14:06","pubTimestamp":1766383579,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念股逆市受压，截至发稿，康龙化成 跌4.14%，药明生物跌3.75%，药明康德跌2.89%，昭衍新药跌2.67%，泰格医药跌2.07%，金斯瑞生物科技跌1.36%。招银国际表示，MSCI中国医疗指数2025年初至今累计上涨51.9%，跑赢MSCI中国指数24.3%。近期，医药板块有所回调。政策端方面，《生物安全法案》虽已签署生效，但鉴于其未波及Medicaid和Medicare的采购且对关联方定义明确，以及中国CXO美国行政机构收入占比较小，该机构预计该法案对中国CXO企业实质经营影响有限。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972004","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516902.SGD","LU0516422440.USD","09939","BK1576","LU0516423091.SGD","LU0327786744.USD","LU1242518931.SGD","LU0708995583.HKD","BK1574","300759","LU2125910500.SGD","03347","02359","LU0819121731.USD","LU0823426308.USD","LU1720050803.USD","LU2039709279.SGD","LU0417516738.SGD","LU0320764599.SGD","HK0000320223.HKD","HK0000306685.HKD","LU0326950275.SGD","01548","LU0572944931.SGD","BK1141","LU0140636845.USD","HK0000320264.USD","BK1589","BK1610","BK1161","CXO","LU1880383366.USD","LU0359202008.SGD","LU0348735423.USD","LU0051755006.USD","LU1046422090.SGD","HK0000306701.USD","06127","SG9999002463.SGD","BK0216","LU3063872942.SGD","159938","LU0456846285.SGD","03759","02269","LU0359201612.USD","LU0516423174.USD","LU0348825331.USD","SG9999002562.SGD","BK1583"],"gpt_icon":0},{"id":"2593489555","title":"医药行业周报：本周申万医药生物指数下跌0.1% 关注国内药企出海动态","url":"https://stock-news.laohu8.com/highlight/detail?id=2593489555","media":"申万宏源研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593489555?lang=zh_cn&edition=full","pubTime":"2025-12-22 00:00","pubTimestamp":1766332800,"startTime":"0","endTime":"0","summary":"本期投资提示：市场表现：本周申万医药生物指数下跌0.1%，同期上证指数上涨0.03%，万得全A下跌0.5%。本周医药生物指数在31 个申万一级子行业中表现排名第22。12 月18 日，诺和诺德宣布向FDA 递交CagriSema 上市申请，这是全球首款GLP-1+Amylin 联合疗法。全球首个用于治疗成瘾类精神疾病的侵入式脑机接口获批，福瑞医科及百普赛斯拟赴港上市。12 月16 日，恒瑞医药持股公司Kailera 启动HRS-9531 三项全球III 期临床，覆盖肥胖合并及不合并糖尿病适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222182625a6c10bdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222182625a6c10bdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02359","LU1046422090.SGD","BK1141","LU2125910500.SGD","BK1576","06127","LU2242644610.SGD","LU2045819591.USD","LU0708995583.HKD","LU0320764599.SGD","LU0052750758.USD","BK1583"],"gpt_icon":0},{"id":"2593121986","title":"医药生物行业周报：推荐CXO+科研服务板块的估值切换机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2593121986","media":"开源证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593121986?lang=zh_cn&edition=full","pubTime":"2025-12-21 00:00","pubTimestamp":1766246400,"startTime":"0","endTime":"0","summary":"全球融资环境整体已处于回暖阶段，CRO 需求端已出现明确拐点，继续推荐2026 年创新药产业链整体性的机会。随着需求端持续改善，我们预计头部CXO+科研服务公司业绩有望持续改善，当前位置看2026 年估值性价比明显，首推相关标的估值切换的机会。医药布局思路及推荐标的整体上，我们持续看好创新药及其产业链，创新药方向重点推荐小核酸赛道的机会，并重点推荐头部CXO+科研服务估值切换的机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251221173627a6bd0916&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251221173627a6bd0916&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06127","BK1593","02269","HK0000165453.HKD","BK1583","01530"],"gpt_icon":0},{"id":"2593055142","title":"6家CRO，赚了！","url":"https://stock-news.laohu8.com/highlight/detail?id=2593055142","media":"药通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593055142?lang=zh_cn&edition=full","pubTime":"2025-12-20 12:42","pubTimestamp":1766205731,"startTime":"0","endTime":"0","summary":"药明康德作为CRO行业大哥，对于资源端的布局自然走在前列，其在2020年收购广东泰盛，目前存栏2万余只，强化了一体化供应链。昭衍新药是国内自有实验猴资源多的CRO之一，据悉，2022年其收购广西玮美和云南英茂，并结合自建玉林农场，饲养能力1.5万只，目前自有猴只总量已超2万只。此番实验猴涨价，多家CRO重金求猴，而这6家CRO凭借自有布局直接获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220125758a6b99c01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220125758a6b99c01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03759","06127","BK1576","BK1141"],"gpt_icon":0},{"id":"2592150531","title":"每日卖空追踪 | 昭衍新药 12月19日卖空量成交22.22万股，卖空比例为4.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592150531","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592150531?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:30","pubTimestamp":1766133035,"startTime":"0","endTime":"0","summary":"昭衍新药北京时间12月19日，跌2.41%，卖空量成交22.22万股，较上一交易日减少2.93%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219163624a6b64777&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219163624a6b64777&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","06127","BK1576"],"gpt_icon":0},{"id":"2592115056","title":"昭衍新药12月19日遭主力抛售47.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592115056","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592115056?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:16","pubTimestamp":1766132160,"startTime":"0","endTime":"0","summary":"12月19日, 昭衍新药股价跌2.41%，报收21.88元，成交金额1.1亿元，换手率4.07%，振幅6.33%，量比0.38。昭衍新药今日主力资金净流出47.2万元，上一交易日主力净流出34.2万元。该股近5个交易日上涨2.44%，主力资金累计净流入447.3万元；近20日主力资金累计净流入8076.2万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219162227a6b635b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219162227a6b635b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06127","BK1576","BK1141"],"gpt_icon":0},{"id":"2592581701","title":"医药生物行业周报（12月第2周）：CXO有望迎来修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2592581701","media":"世纪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592581701?lang=zh_cn&edition=full","pubTime":"2025-12-19 10:08","pubTimestamp":1766110102,"startTime":"0","endTime":"0","summary":"CXO有望迎来修复。CXO业绩和新增订单开始好转，本周市场开始关注临床前安评试验资产食蟹猴。我们认为CXO作为创新药产业链上游，行业经历过完整周期，有望受益于国产创新药竞争力提升带来的景气度回升，看好CXO在业绩和估值端迎来双重修复。北方省份哨点医院报告的比例为7.9%，低于前一周水平，高于2022年、2023年和2024年同期水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219100847a45dd70f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219100847a45dd70f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06127","BK1576","BK1141"],"gpt_icon":0},{"id":"2592163639","title":"昭衍新药：公司具备OECD的GLP认证资质","url":"https://stock-news.laohu8.com/highlight/detail?id=2592163639","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592163639?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:10","pubTimestamp":1765980600,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月17日，昭衍新药在互动平台回答投资者提问时表示，公司具备OECD的GLP认证资质，可以承接相关项目。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-17/doc-inhccnef9221279.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-17/doc-inhccnef9221279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603127","BK0216","BK4590","GLP","BK1576","BK4144","06127","BK1141"],"gpt_icon":0},{"id":"2592043993","title":"每日卖空追踪 | 昭衍新药 12月17日卖空量成交20.92万股，卖空比例为1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592043993","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592043993?lang=zh_cn&edition=full","pubTime":"2025-12-17 16:30","pubTimestamp":1765960235,"startTime":"0","endTime":"0","summary":"昭衍新药北京时间12月17日，涨10.36%，卖空量成交20.92万股，较上一交易日增加8.06%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217163557a6ad2705&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217163557a6ad2705&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06127","BK1576","BK1141"],"gpt_icon":0},{"id":"1150760712","title":"港股异动｜生物医药股上扬，药捷安康涨超17%，昭衍新药涨超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150760712","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150760712?lang=zh_cn&edition=full","pubTime":"2025-12-17 10:50","pubTimestamp":1765939813,"startTime":"0","endTime":"0","summary":"轩竹生物涨超5%，银诺医药涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"22a0e03e703ab82b83863db78ab69d04","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","02575","06127","02591"],"gpt_icon":0},{"id":"2592495423","title":"港股异动 | 昭衍新药(06127)涨超8% 实验猴价格近期上行 机构料供需偏紧状态或将维持","url":"https://stock-news.laohu8.com/highlight/detail?id=2592495423","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592495423?lang=zh_cn&edition=full","pubTime":"2025-12-17 09:39","pubTimestamp":1765935593,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昭衍新药涨超8%，截至发稿，涨8.21%，报22.14港元，成交额3986.2万港元。方正证券12月15日发布的研报指出，实验猴作为临床前安评的刚性资源，随着临床前CRO订单稳步回暖，需求提升；且供给侧短期扩产难度较大，部分猴场表示产能已预定至2026年一季度，预计供需偏紧状态或将维持，短期价格有望进一步上行。方正证券认为，头部CRO战略资源储备丰富，有望受益于行业回暖+猴价公允价值收益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382410.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06127","603127","BK1576","BK0216","BK1141"],"gpt_icon":0},{"id":"2591624072","title":"每日卖空追踪 | 昭衍新药 12月15日卖空量成交72.86万股，卖空比例为5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591624072","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591624072?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787435,"startTime":"0","endTime":"0","summary":"昭衍新药北京时间12月15日，涨1.97%，卖空量成交72.86万股，较上一交易日减少31.85%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163603a6a4598e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163603a6a4598e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","06127","BK1576"],"gpt_icon":0},{"id":"2591616750","title":"智通AH统计|12月15日","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616750","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591616750?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:15","pubTimestamp":1765786506,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止12月15日收盘，东北电气、京城机电股份、弘业期货分列AH溢价率前三位，溢价率分别为900.00%、266.67%、265.78%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-11.03%、-0.77%、1.62%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00177","01033","BK1594","LU0244354667.USD","BK1562","00638","02218","00548","03968","LU1504937902.USD","02865","02359","00300","01988","02899","02338","01276","LU0348827113.USD","01618","01812","03606","BK1565","00038","LU1522347837.USD","06127","00916","03750","00317","01339","01528","399300","06818","LU1105468828.SGD","IE00B29SXG58.USD","00042","02238","LU0823426480.USD","LU0886674414.USD","01108","00553","01057","01349","03678","06826","00187","159982","03143"],"gpt_icon":1},{"id":"2591269466","title":"昭衍新药午前涨超4% 本月股价已累计涨超三成","url":"https://stock-news.laohu8.com/highlight/detail?id=2591269466","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591269466?lang=zh_cn&edition=full","pubTime":"2025-12-15 11:59","pubTimestamp":1765771140,"startTime":"0","endTime":"0","summary":"　　昭衍新药午前涨超4%，本月股价已累计涨超三成。截至发稿，股价上涨4.23%，报22.18港元，成交额2.11亿港元。　　根据北京商报，12月9日实验猴价格呈加速上涨趋势，大约14万元/只。　　据方正证券测算，以昭衍新药为例，假设按照2024年实验猴均价计入公允价值8.49万/只，2025Q4价格提升至14万/只，假设猴场出栏率为17%，按照已知23200只猴测算，毛估计2025年新增公允价值约2.2亿。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-12-15/doc-inhawauf3941208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1576","BK0216","BK1141","06127","603127"],"gpt_icon":0},{"id":"2591637009","title":"“天价猴”再临CRO，20cm大红柱吹响昭衍新药股价反攻号角？","url":"https://stock-news.laohu8.com/highlight/detail?id=2591637009","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591637009?lang=zh_cn&edition=full","pubTime":"2025-12-14 08:30","pubTimestamp":1765672226,"startTime":"0","endTime":"0","summary":"在股价阴跌了4个多月后，昭衍新药靠着一根“20cm大红柱”将市场目光重新拉回到这家安评龙头以及近期再度暴涨的“猴价”上。但实际上，昭衍新药此次股价新高之路并不平坦。12月12日一根“20cm大红柱”则将昭衍新药收盘价拉至21.25港元，也让筹码获利比例从12月11日的32.02%大幅升至12月12日的78.84%。从最新的Q3财报来看，2025年前三季度，昭衍新药新签订单金额达16.4亿元，同比增长17.1%，其中第三季度增速达24%，已出现回暖迹象。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381223.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1576","BK0216","BK1141","603127","06127"],"gpt_icon":0},{"id":"2591632904","title":"英伟达连续布局13家企业，AI制药3个方向梳理（附列表）","url":"https://stock-news.laohu8.com/highlight/detail?id=2591632904","media":"投研大叔","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591632904?lang=zh_cn&edition=full","pubTime":"2025-12-13 19:40","pubTimestamp":1765626014,"startTime":"0","endTime":"0","summary":"今天介绍下AI制药，英伟达在过去2年投资13家AI药企，推出BioNeMo生物分子AI框架已经覆盖上百家药企，英硅智能ISM001-055进入临床III期，成为首个跨越临床II期的AI药物，从之前的布局到如今逐渐突破，商业价值正在逐渐被验证。从大叔个人来看，还有一些罕见病，由于患者少，研发不划算，而AI能快速低成本设计药物，让更多罕见病有药可治。近期热门文章HW组建医疗卫生军团，AI医疗爆发！","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213194757a4470c58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213194757a4470c58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1280957306.USD","NVD2.UK","SNVD.UK","LU2505996681.GBP","LU0308772762.SGD","LU0719512351.SGD","LU2860962120.EUR","SG9999004303.SGD","NVDY","IE00BJJMRY28.SGD","LU1914381329.SGD","02359","LU2473716301.USD","LU1988902786.USD","IE000ITXATA3.USD","LU2237438978.USD","LU0158827948.USD","LU1839511570.USD","NVIW.SI","LU2463028550.USD","LU0096362180.USD","LU2065171311.SGD","LU2505996509.AUD","NVDS","LU0320765059.SGD","02228","NVD","LU2249611893.SGD","NVD3.UK","IE00BDCRKT87.USD","LU0157215616.USD","LU1496350171.SGD","LU0444973449.USD","LU2089284900.SGD","02196","IE0034235188.USD","LU0274383776.USD","06821","NVDU","SGXZ81514606.USD","LU2191332357.HKD","NVDA","LU1145028129.USD","NVDD","2NVD.UK","NVDS.UK","NVDX","06127","LU2602419157.SGD","3NVD.UK","LU1642822529.SGD","03759","LU2592432038.USD","01093","IE000YTNTUN2.SGD","LU2420271590.USD"],"gpt_icon":1}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0841},{"period":"1month","weight":0.3491},{"period":"3month","weight":-0.0521},{"period":"6month","weight":0.4611},{"period":"1year","weight":1.4746},{"period":"ytd","weight":1.3768}],"compareEarnings":[{"period":"1week","weight":0.0213},{"period":"1month","weight":0.022},{"period":"3month","weight":-0.0281},{"period":"6month","weight":0.0596},{"period":"1year","weight":0.2963},{"period":"ytd","weight":0.2849}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"北京昭衍新药研究中心股份有限公司是一家主要从事新药药理毒理学研究的中国公司。该公司通过三个分部开展业务。药物非临床研究服务分部主要提供药品非临床安全性评价服务、药效学研究服务、药代动力学研究服务。临床服务及其他分部主要提供药品上市前的临床服务以及药物警戒服务。实验模型供应分部为实验模型及其附属产品的生产和销售。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.111186},{"month":2,"riseRate":0.75,"avgChangeRate":0.137943},{"month":3,"riseRate":0.4,"avgChangeRate":-0.007614},{"month":4,"riseRate":0.2,"avgChangeRate":-0.110118},{"month":5,"riseRate":0.8,"avgChangeRate":0.111301},{"month":6,"riseRate":0.6,"avgChangeRate":0.067356},{"month":7,"riseRate":0.8,"avgChangeRate":0.10434},{"month":8,"riseRate":0,"avgChangeRate":-0.152531},{"month":9,"riseRate":0.6,"avgChangeRate":0.016217},{"month":10,"riseRate":0.2,"avgChangeRate":-0.062992},{"month":11,"riseRate":0.4,"avgChangeRate":0.019594},{"month":12,"riseRate":0.6,"avgChangeRate":0.02093}],"exchange":"SEHK","name":"昭衍新药","nameEN":"JOINN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(06127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,06127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(06127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}